Monoclonal antibodies may be a better choice than convalescent plasma for treating COVID-19

Monoclonal antibodies may be a better choice than convalescent plasma for treating COVID-19

Monoclonal antibodies may be a better choice than convalescent plasma for treating COVID-19

A team of researchers from the Netherlands demonstrated that prophylactic treatment with a high dose of human convalescent plasma or by using concentrated monoclonal antibodies could protect against disease following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in an animal model. However, no protective effect was observed with a ten-fold lower dose of convalescent plasma. The results are currently available on the bioRxiv* preprint server.